加载中
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
常规交易时段
US$28.36
−US$0.15 · -0.53%
盘中时间采用ET。市场数据可能有所延迟。
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
日内区间
当前US$28.36
52周区间
当前US$28.36
盘中时间采用ET。市场数据可能有所延迟。
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
日内区间
当前US$28.36
52周区间
当前US$28.36
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 43.1万 USD | — | — | — | — |
| 毛利 | −43.1万 USD | — | — | — | — |
| 研究与开发 | 3.45亿 USD | 1.02亿 USD | 6380.6万 USD | 5423.4万 USD | 4498.1万 USD |
| 销售、一般及管理费用 | 4838.7万 USD | 4927.7万 USD | 3702.1万 USD | 1612.1万 USD | 1070.1万 USD |
| 营业费用 | 3.93亿 USD | 1.51亿 USD | 1.01亿 USD | 7035.5万 USD | 5568.2万 USD |
| 利息收入 | 3370.4万 USD | 4094万 USD | 1502万 USD | 158.9万 USD | 70.3万 USD |
| 利息支出 | — | 9.4万 USD | 8.8万 USD | 5.9万 USD | 1.8万 USD |
| 折旧和摊销 | 43.1万 USD | 34.6万 USD | 29.2万 USD | 29.1万 USD | 29.6万 USD |
| 营业利润 | −3.93亿 USD | −1.51亿 USD | −1.01亿 USD | −7035.5万 USD | −5568.2万 USD |
| 净利润 | −3.6亿 USD | −1.1亿 USD | −8589.5万 USD | −6886.7万 USD | −5499万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$97.80
上涨空间 244.85%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.15亿0.00%2.3万亿 USD0.03%US$381.51-0.11%
State Street SPDR S&P Biotech ETFXBI9668.32万0.98%98.74亿 USD0.35%US$151.47-1.50%
Vanguard Morningstar Small-Cap ETFVB8314.12万0.04%1853亿 USD0.03%US$288.72-0.26%
Vanguard Morningstar Small-Cap Growth ETFVBK4785.4万0.10%447亿 USD0.05%US$341.12-1.05%
Vanguard Extended Market ETFVXF4427.72万0.05%954亿 USD0.05%US$234.01-0.42%
Schwab U.S. Small-Cap ETFSCHA1828.41万0.08%218.24亿 USD0.03%US$32.7301-0.18%
iShares Russell Mid-Cap ETFIWR1434.5万0.03%567.65亿 USD0.18%US$109.62-0.19%
Vanguard Health Care ETFVHT1101.58万0.05%220亿 USD0.09%US$319.67+0.21%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell Mid-Cap ETFIWRVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
